<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7464173\results\search\disease\results.xml">
  <result pre="search for new therapies that would be effective in controlling" exact="viral" post="infections. The aim of this study was the synthesis"/>
  <result pre="maximal inhibitory concentration) equal to 0.02 Î¼M. Compound 3 inhibits" exact="viral" post="replication at a level comparable to bevirimat and is"/>
  <result pre="century, the World Health Organization (WHO) recorded many epidemics of" exact="viral" post="diseases. Among the great epidemics of this period were"/>
  <result pre="diseases. Among the great epidemics of this period were severe" exact="acute" post="respiratory syndrome (SARS) in the year 2003, the influenza"/>
  <result pre="Among the great epidemics of this period were severe acute" exact="respiratory" post="syndrome (SARS) in the year 2003, the influenza H1N1"/>
  <result pre="the great epidemics of this period were severe acute respiratory" exact="syndrome" post="(SARS) in the year 2003, the influenza H1N1 pandemic"/>
  <result pre="year 2003, the influenza H1N1 pandemic in 2009, Middle East" exact="respiratory" post="syndrome (MERS) in 2012, and the Zika virus in"/>
  <result pre="2003, the influenza H1N1 pandemic in 2009, Middle East respiratory" exact="syndrome" post="(MERS) in 2012, and the Zika virus in 2005,"/>
  <result pre="and the Zika virus in 2005, as well as the" exact="HIV/AIDS" post="pandemic, which peaked in 2005â€&quot;2012 [1]. The beginning of"/>
  <result pre="has been reported in relation to viruses such as HIV," exact="hepatitis" post="virus C (HCV), various types of influenza viruses, SARS,"/>
  <result pre="hepatitis virus C (HCV), various types of influenza viruses, SARS," exact="hepatitis" post="B virus (HBV), herpes viruses (HSV), human enterovirus 71"/>
  <result pre="various types of influenza viruses, SARS, hepatitis B virus (HBV)," exact="herpes" post="viruses (HSV), human enterovirus 71 (EV71), and Epsteinâ€&quot;Barr virus"/>
  <result pre="maturation [5]. Among the drugs used in the treatment of" exact="viral" post="infections, compounds containing phosphate or the phosphonate moiety within"/>
  <result pre="important place. Examples of such drugs include cidofovir (active against" exact="herpes" post="simplex virus HSV-1 and HSV-2, as well as Epsteinâ€&quot;Barr"/>
  <result pre="(active against HIV-1, HIV-2, and HBV), and foscarnet (active against" exact="herpes" post="viruses and HIV) [6,7,8]. Indeed, several patents describing phosphorus"/>
  <result pre="IC50 value similar to that of BVM, and with a" exact="lower" post="cytotoxicity. The results of molecular docking into the Gag"/>
  <result pre="positive-strand RNA viruses that have glycoprotein spikes projecting from their" exact="viral" post="envelopes and thus exhibit a corona or halo-like appearance"/>
  <result pre="drugs that may be useful in the early stages of" exact="infection" post="[15]. The subject of this work is the synthesis"/>
  <result pre="spectrometer (Bruker, Billerica, MA, USA) in deuterated CDCl3, using the" exact="residual" post="solvent signal as an internal standard. Chemical shifts values"/>
  <result pre="HR-MS (APCI) m/z: C34H58O5P [(Mâ€&quot;H)âˆ’], Calc. 577.4022; Found 577.4011. 2.1.2." exact="General" post="Method of Synthesis 3-Carboxyacyl Derivatives 3â€&quot;5 To the solution"/>
  <result pre="run in triplicate. A wild-type HIV-1 was isolated from the" exact="HIV-positive" post="patient in the Laboratory of Virology of the National"/>
  <result pre="days, HIV replication was evaluated through the measurement of secreted" exact="viral" post="protein p24 carried out with the enzyme-linked immunosorbent assay"/>
  <result pre="Target macromolecules for molecular docking studies were obtained from the" exact="Protein" post="Data Bank (https://www.rcsb.org/; Research Collaboratory for Structural Bioinformatics, USA)."/>
  <result pre="obtained from the Protein Data Bank (https://www.rcsb.org/; Research Collaboratory for" exact="Structural" post="Bioinformatics, USA). We used crystal structure of the CA-CTD-SP1"/>
  <result pre="spike ectodomain (PDB IDs: 5I4T, 5R7Z, 6M71, and 6VYB respectively)." exact="Incomplete" post="or missing side chains of CA-CTD-SP1 protein were restored"/>
  <result pre="[26] was employed to perform molecular docking. AutoDock Vina incorporates" exact="limited" post="flexibility in the receptor, and it combines an empirical"/>
  <result pre="Y = 0.010 and Z = 3.855 for HIV-1 Gag" exact="and X" post="= âˆ’27.585, Y = 2.501 and Z = 28.139"/>
  <result pre="= 0.00 and Z = 0.00 for SARS-CoV-2 E protein" exact="and X" post="= 177,973, Y = 198.333, Z = 227.722 Ã…"/>
  <result pre="Y = âˆ’22.675 and Z = âˆ’43.271 for hypoxanthine-guanine phosphoribosyltransferase" exact="and X" post="= âˆ’17.201, Y = 20.346, Z = 22.393 Ã…"/>
  <result pre="release of immature virion outside host cell. During maturation process," exact="viral" post="protease cleaves Gag precursor protein to individual matrix (MA),"/>
  <result pre="(NC) peptides. This step is essential to produce mature and" exact="infectious" post="virions. Recent studies report that the immature CA-CTD-SP1 assembles"/>
  <result pre="of CA and SP1 of HIV-1 Gag deposited in the" exact="Protein" post="Data Bank (PBD ID 5I4T), one active site cavity"/>
  <result pre="Results obtained with Vina indicate that compound 3 exhibits a" exact="lower" post="binding energy compared to the reference BVM (Table 2)."/>
  <result pre="to cellular proteins was carried out. It is known that" exact="deficiency" post="and inhibition of some proteins important in normal cellular"/>
  <result pre="docking for the target proteins, all tested compounds showed a" exact="lower" post="degree of fit to tested proteins compared to BVM."/>
  <result pre="[53,54]. It has been suggested by several studies that the" exact="absence of" post="the SARS-COV-2 E protein may result in an â€œattenuated"/>
  <result pre="characteristic corolla structure on the membrane of the virion [55]." exact="Structural" post="integrity of spike and cleavage activation play a key"/>
  <result pre="inhibitor [18] can inhibit the virus by inhibiting synthesis of" exact="viral" post="nucleic acid, and has been recently authorized for emergency"/>
  <result pre="acid, and has been recently authorized for emergency use in" exact="acute" post="COVID-19 patients. On 31 January 2020, the New England"/>
  <result pre="0.03 ÂµM for 6 and BVM, respectively), and with a" exact="lower" post="cytotoxicity (CC50 = 68 ÂµM and 29 ÂµM for"/>
  <result pre="and compounds 4 and 6) were selected based on a" exact="lower" post="negative dock energy value. Detailed interactions between ligands and"/>
  <result pre="fluctuations of RMSD of all proteins indicate that they reached" exact="stable" post="conformation (Supplementary Materials Figures S7â€&quot;S9). 4. Conclusions The new"/>
  <result pre="published version of the manuscript. Funding This research received no" exact="external" post="funding. Conflicts of Interest The authors declare no conflict"/>
  <result pre="Chem.2008166778678210.1016/j.bmc.2008.05.05818554916 8.BroganelliP.ChiarettaA.FragnelliB.BernengoM.G.Intralesional cidofovir for the treatment of multiple and recalcitrant" exact="cutaneous" post="viral wartsDermatol. Ther.20122546847110.1111/j.1529-8019.2012.01477.x23046027 9.BoojamraC.G.CannizzaroC.E.ChenJ.M.ChenX.ChoA.ChongL.S.FardisM.JinH.HirshmannR.HuangA.X.et al.Gilead Sciences Inc., Antiviral Phosphonate"/>
  <result pre="8.BroganelliP.ChiarettaA.FragnelliB.BernengoM.G.Intralesional cidofovir for the treatment of multiple and recalcitrant cutaneous" exact="viral" post="wartsDermatol. Ther.20122546847110.1111/j.1529-8019.2012.01477.x23046027 9.BoojamraC.G.CannizzaroC.E.ChenJ.M.ChenX.ChoA.ChongL.S.FardisM.JinH.HirshmannR.HuangA.X.et al.Gilead Sciences Inc., Antiviral Phosphonate AnalogsU.S."/>
  <result pre="plant terpenoids and lignoids possess potent antiviral activities against severe" exact="acute" post="respiratory syndrome coronavirusJ. Med. Chem.2007504087409510.1021/jm070295s17663539 20.HashimotoF.KashiwadaY.CosentinoL.M.ChenC.H.GarrettP.E.LeeK.H.Anti-AIDS agents-XXVII. Synthesis and"/>
  <result pre="terpenoids and lignoids possess potent antiviral activities against severe acute" exact="respiratory" post="syndrome coronavirusJ. Med. Chem.2007504087409510.1021/jm070295s17663539 20.HashimotoF.KashiwadaY.CosentinoL.M.ChenC.H.GarrettP.E.LeeK.H.Anti-AIDS agents-XXVII. Synthesis and anti-HIV"/>
  <result pre="and lignoids possess potent antiviral activities against severe acute respiratory" exact="syndrome" post="coronavirusJ. Med. Chem.2007504087409510.1021/jm070295s17663539 20.HashimotoF.KashiwadaY.CosentinoL.M.ChenC.H.GarrettP.E.LeeK.H.Anti-AIDS agents-XXVII. Synthesis and anti-HIV activity"/>
  <result pre="anti-HIV compoundsJ. Virol. Methods19882030932110.1016/0166-0934(88)90134-62460479 22.ViscidiR.FarzadeganH.LeisterF.FranciscoM.L.YolkenR.Enzyme immunoassay for detection of human" exact="immunodeficiency" post="virus antigens in cells culturesJ. Clin. Microbiol.19882645345810.1128/JCM.26.3.453-458.19882451678 23.FrischM.J.TrucksG.W.SchlegelH.B.ScuseriaG.E.RobbM.A.CheesemanJ.R.ScalmaniG.BaroneV.PeterssonG.A.NakatsujiH.et al.Gaussian"/>
  <result pre="mitochondria aconitase inactivationJ. Neurochem.20017874675510.1046/j.1471-4159.2001.00457.x11520895 46.VempatiU.D.DiazF.BarrientosA.NarisawaS.MianA.M.MillÃ¡nJ.L.BoiseL.H.MoraesC.T.Role of Cytochrome c in apoptosis:" exact="Increased" post="sensitivity to tumor necrosis factor alpha is associated with"/>
  <result pre="Neurochem.20017874675510.1046/j.1471-4159.2001.00457.x11520895 46.VempatiU.D.DiazF.BarrientosA.NarisawaS.MianA.M.MillÃ¡nJ.L.BoiseL.H.MoraesC.T.Role of Cytochrome c in apoptosis: Increased sensitivity to" exact="tumor" post="necrosis factor alpha is associated with respiratory defects but"/>
  <result pre="Increased sensitivity to tumor necrosis factor alpha is associated with" exact="respiratory" post="defects but not with lack of Cytochrome c releaseMol."/>
  <result pre="Cell. Biol.2007271771178310.1128/MCB.00287-0617210651 47.LaemmleA.HahnD.HuL.RÃ¼fenachtV.GautschiM.LeibundgutK.NuofferJ.-M.HÃ¤berleJ.Fatal hyperammonemia and carbamoyl phosphate synthetase 1 (cps1)" exact="deficiency" post="following high-dose chemotherapy and autologous hematopoietic stem cell transplantationMol."/>
  <result pre="and autologous hematopoietic stem cell transplantationMol. Genet. Metab.201511443844410.1016/j.ymgme.2015.01.00225639153 48.KostalovaE.PavelkaK.VlaskovaH.MusalkovaD.StiburkovaB.Hyperuricemia and" exact="gout" post="due to deficiency of hypoxanthine-guanine phosphoribosyltransferase in female carriers:"/>
  <result pre="stem cell transplantationMol. Genet. Metab.201511443844410.1016/j.ymgme.2015.01.00225639153 48.KostalovaE.PavelkaK.VlaskovaH.MusalkovaD.StiburkovaB.Hyperuricemia and gout due to" exact="deficiency" post="of hypoxanthine-guanine phosphoribosyltransferase in female carriers: New insight to"/>
  <result pre="48.KostalovaE.PavelkaK.VlaskovaH.MusalkovaD.StiburkovaB.Hyperuricemia and gout due to deficiency of hypoxanthine-guanine phosphoribosyltransferase in" exact="female" post="carriers: New insight to differential diagnosisCase Rep. Clin. Chim."/>
  <result pre="Coronavirus (SARS-CoV-2) in light of past human coronavirus outbreaksPathogens2020918610.3390/pathogens9030186 54.Regla-NavaJ.A.Nieto-TorresJ.L.Jimenez-GuardeÃ±oJ.M.Fernandez-DelgadoR.FettC.CastaÃ±o-RodrÃ­guezC.PerlmanS.EnjuanesL.DeDiegoM.L.Severe" exact="acute" post="respiratory syndrome coronaviruses with mutations in the E protein"/>
  <result pre="(SARS-CoV-2) in light of past human coronavirus outbreaksPathogens2020918610.3390/pathogens9030186 54.Regla-NavaJ.A.Nieto-TorresJ.L.Jimenez-GuardeÃ±oJ.M.Fernandez-DelgadoR.FettC.CastaÃ±o-RodrÃ­guezC.PerlmanS.EnjuanesL.DeDiegoM.L.Severe acute" exact="respiratory" post="syndrome coronaviruses with mutations in the E protein are"/>
  <result pre="in light of past human coronavirus outbreaksPathogens2020918610.3390/pathogens9030186 54.Regla-NavaJ.A.Nieto-TorresJ.L.Jimenez-GuardeÃ±oJ.M.Fernandez-DelgadoR.FettC.CastaÃ±o-RodrÃ­guezC.PerlmanS.EnjuanesL.DeDiegoM.L.Severe acute respiratory" exact="syndrome" post="coronaviruses with mutations in the E protein are attenuated"/>
  <result pre="Med.202038292993610.1056/NEJMoa200119132004427 59.GuptaM.K.VemulaS.DondeR.GoudaG.BeheraL.VaddeR.In-silico approaches to detect inhibitors of the human severe" exact="acute" post="respiratory syndrome coronavirus envelope protein ion channelJ. Biomol. Struct."/>
  <result pre="59.GuptaM.K.VemulaS.DondeR.GoudaG.BeheraL.VaddeR.In-silico approaches to detect inhibitors of the human severe acute" exact="respiratory" post="syndrome coronavirus envelope protein ion channelJ. Biomol. Struct. Dyn.202010.1080/07391102.2020.1751300"/>
  <result pre="approaches to detect inhibitors of the human severe acute respiratory" exact="syndrome" post="coronavirus envelope protein ion channelJ. Biomol. Struct. Dyn.202010.1080/07391102.2020.1751300 60.TaiW.HeL.ZhangX.PuJ.VoroninD.JiangS.ZhouY.DuL.Characterization"/>
  <result pre="novel coronavirus: Implication for development of RBD protein as a" exact="viral" post="attachment inhibitor and vaccineCell Mol. Immunol.20201710.1038/s41423-020-0400-432203189 Figures, Scheme and"/>
  <result pre="used for docking study for SARS-CoV-2. biomolecules-10-01148-t001_Table 1Table 1 Anti-human" exact="immunodeficiency" post="virus (HIV)-1 replication activities in human immunodeficiency virus (HIV)-infected"/>
  <result pre="1Table 1 Anti-human immunodeficiency virus (HIV)-1 replication activities in human" exact="immunodeficiency" post="virus (HIV)-infected CEM-T4 cell line. Compound CC50 (ÂµM) IC50"/>
  <result pre="3Table 3 Toxicity and side effect-causing protein target of drugs." exact="Protein" post="Physiological Function Site of Action Effect of Deficiency/Inhibition Ref."/>
  <result pre="of Action Effect of Deficiency/Inhibition Ref. pyruvate kinase glycolysis cytosol" exact="hemolytic anemia" post="[44] aconitase citric acid cycle mitochondria neurotoxicity [45] cytochrome"/>
  <result pre="Action Effect of Deficiency/Inhibition Ref. pyruvate kinase glycolysis cytosol hemolytic" exact="anemia" post="[44] aconitase citric acid cycle mitochondria neurotoxicity [45] cytochrome"/>
  <result pre="glycolysis cytosol hemolytic anemia [44] aconitase citric acid cycle mitochondria" exact="neurotoxicity" post="[45] cytochrome c oxidative phosphorylation mitochondria increased sensitivity to"/>
  <result pre="urea cycle mitochondria hyperammonemia [47] hypoxanthine-guanine phosphoribosyltransferase nucleotide biosynthesis mitochondria" exact="hyperuricemia" post="[48] glutamate dehydrogenase amino acid degradation mitochondria nephrotoxicity [49]"/>
 </snippets>
</snippetsTree>
